GlassScriptPhysician profile
Mark R Harter
NPI 1518946078
$1,078.69
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $58.43 · 2021: $85.18 · 2022: $68.81 · 2023: $163 · 2024: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $244.67 | 2019-2020 | |
| Novo Nordisk INC | $197.05 | 2019-2024 | Wegovy, Saxenda |
| Pfizer INC. | $99.66 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $85.51 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $74.47 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $59.09 | 2019-2022 | |
| Dexcom, INC. | $43.50 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $43.42 | 2019 | |
| Abbvie INC. | $39.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.44 | 2019-2020 | |
| Averitas Pharma INC. | $29.66 | 2024 | Qutenza |
| Amarin Pharma, INC. | $27.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.90 | 2021 | |
| Lilly USA, LLC | $14.70 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.01 | 2019 | |
| Biodelivery Sciences International, INC. | $13.29 | 2021 | |
| Abbott Laboratories | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.